Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPL | P40238 | 3/20 | 0.40 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24428023 | 0.80 | CREBBP (0.37) | FLT3PDE3BPDE3AS1PR1TGFBR1 | |
| SCHEMBL24427480 | 0.75 | MAPK14 (0.36) | — | |
| SCHEMBL24427537 | 0.75 | TRPA1 (0.35) | CYP1A1PDE3BPDE3A | |
| SCHEMBL17832298 | 0.75 | KDM4E (0.42) | ACHESMN1; SMN2PARP1 | |
| SCHEMBL24427241 | 0.74 | CYP2A6 (0.43) | MPLCDK2FLT3CCNA1S1PR1 | |
| SCHEMBL29403371 | 0.72 | KIF11 (0.50) | MPLARFFAR4KIF11 | |
| SCHEMBL349356 | 0.72 | KIF11 (0.50) | MPLARFFAR4KIF11 | |
| SCHEMBL24427863 | 0.71 | KDM4E (0.31) | SMN1; SMN2 | |
| SCHEMBL24427514 | 0.70 | PDPK1 (0.52) | CDK2TGFBR1 | |
| SCHEMBL24427524 | 0.70 | SCN9A (0.46) | FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11518766-B2 | Tricyclic compound, preparation method therefor and use thereof | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD. (CN) | 2022-12-06 | — | — | US | disclosed |
| EP-3998263-A1 | TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) | 2022-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11518766-B2 | Tricyclic compound, preparation method therefor and use thereof | TFPI, TFPI2, F11 | MPL 610/4885CYP1A1 721/4885CDK2 2408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.